Niagen Bioscience (NAGE) Current Deferred Revenue (2011 - 2026)
Niagen Bioscience's (NAGE) quarterly Current Deferred Revenue came in at $380000.0 in Q1 2026, up 83.57% year-on-year from $207000.0 in Q1 2025, and down 4.76% on a QoQ basis from $399000.0 in Q4 2025.
Niagen Bioscience (NAGE) Current Deferred Revenue (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has 13 years of Current Deferred Revenue data on file, last reported at $380000.0 in Q1 2026.
- On a quarterly basis, Current Deferred Revenue rose 83.57% year-over-year to $380000.0 in Q1 2026; TTM through Mar 2026 was $380000.0, a 83.57% increase from a year earlier, with the FY2025 full-year figure at $399000.0, down 34.7% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $380000.0, down from $399000.0 in the prior quarter.
- Over the last five years, Current Deferred Revenue for NAGE reached as high as $611000.0 in Q4 2024 and fell as low as $141000.0 in Q1 2022.
- Historically, Current Deferred Revenue has averaged $240352.9 across 5 years, with a median of $189000.0 in 2023.
- Across the five-year window, Current Deferred Revenue jumped 213.33% in 2024 and plunged 34.7% in 2025, its largest moves.
- Year by year, Current Deferred Revenue stood at $157000.0 in 2022, then advanced by 24.2% to $195000.0 in 2023, then soared by 213.33% to $611000.0 in 2024, then sank by 34.7% to $399000.0 in 2025, then declined by 4.76% to $380000.0 in 2026.
- Per Business Quant data, the three most recent Current Deferred Revenue figures were $380000.0 in Q1 2026, $399000.0 in Q4 2025, and $292000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Niagen Bioscience | 253.47 Mn | 186.92 Mn | 19.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 380,000.00 |
| Dec 31, 2025 | 399,000.00 |
| Sep 30, 2025 | 292,000.00 |
| Jun 30, 2025 | 303,000.00 |
| Mar 31, 2025 | 207,000.00 |
| Dec 31, 2024 | 611,000.00 |
| Sep 30, 2024 | 184,000.00 |
| Jun 30, 2024 | 156,000.00 |
| Mar 31, 2024 | 227,000.00 |
| Dec 31, 2023 | 195,000.00 |
| Sep 30, 2023 | 189,000.00 |
| Jun 30, 2023 | 166,000.00 |
| Mar 31, 2023 | 148,000.00 |
| Dec 31, 2022 | 157,000.00 |
| Sep 30, 2022 | 158,000.00 |
| Jun 30, 2022 | 173,000.00 |
| Mar 31, 2022 | 141,000.00 |
| Dec 31, 2021 | 161,000.00 |
| Sep 30, 2021 | 175,000.00 |
| Jun 30, 2021 | 210,000.00 |